Los Angeles Capital Management LLC Sells 773 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Los Angeles Capital Management LLC decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,760 shares of the biopharmaceutical company's stock after selling 773 shares during the period. Los Angeles Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $1,850,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $26,000. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. Lynx Investment Advisory bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Finally, Family Firm Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

REGN has been the subject of several recent analyst reports. Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,097.14.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $21.82 during mid-day trading on Thursday, hitting $782.51. 1,086,888 shares of the stock were exchanged, compared to its average volume of 526,637. The company has a market capitalization of $85.99 billion, a P/E ratio of 19.90, a P/E/G ratio of 3.10 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a 50-day simple moving average of $1,000.06 and a 200 day simple moving average of $1,035.67. Regeneron Pharmaceuticals, Inc. has a 12 month low of $780.95 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.